Recombinant Human PAI1 (mutated ) protein (ab93232)

製品の概要

製品の詳細

  • 由来Recombinant
  • 由来Escherichia coli
  • アミノ酸配列
    • 生物種Human

特性

Our Abpromise guarantee covers the use of ab93232 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • 生理活性A triple mutation on the wild-type background makes ab93232 selectively inhibit tPA. Urokinase inhibition is limited to 1/25,000 of tPA inhibition by the P3Tyr-P2Ser-P1Tyr mutation.
  • アプリケーション

    Inhibition Assay

    SDS-PAGE

  • 精製度> 95 % SDS-PAGE.

  • 製品の状態Liquid
  • 備考A triple mutation on the wild-type background makes ab93232 selectively inhibit tPA. Urokinase inhibition is limited to 1/25,000 of tPA inhibition by the P3Tyr-P2Ser-P1Tyr mutation.
  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 0.1M Sodium chloride, 0.05M Sodium phosphate, 1mM EDTA, pH 6.6

関連情報

  • 別名
    • Clade E
    • Endothelial plasminogen activator inhibitor
    • Nexin
    • PAI
    • PAI 1
    • PAI-1
    • PAI1_HUMAN
    • PLANH1
    • Plasminogen activator inhibitor 1
    • Plasminogen activator inhibitor type 1
    • Serine (or cysteine) proteinase inhibitor
    • Serine (or cysteine) proteinase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1
    • Serpin E1
    • Serpin peptidase inhibitor clade E
    • Serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1
    • Serpine 1
    • SERPINE1
    see all
  • 機能This inhibitor acts as 'bait' for tissue plasminogen activator, urokinase, and protein C. Its rapid interaction with TPA may function as a major control point in the regulation of fibrinolysis.
  • 組織特異性Found in plasma and platelets and in endothelial, hepatoma and fibrosarcoma cells.
  • 関連疾患Defects in SERPINE1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1D) [MIM:613329]. It is a hematologic disorder characterized by increased bleeding after trauma, injury, or surgery. Affected females have menorrhagia. The bleeding defect is due to increased fibrinolysis of fibrin blood clots due to deficiency of plasminogen activator inhibitor-1, which inhibits tissue and urinary activators of plasminogen.
    Note=High concentrations of SERPINE1 seem to contribute to the development of venous but not arterial occlusions.
  • 配列類似性Belongs to the serpin family.
  • 翻訳後修飾Inactivated by proteolytic attack of the urokinase-type (u-PA) and the tissue-type (TPA), cleaving the 369-Arg-
    -Met-370 bond.
  • 細胞内局在Secreted.
  • Information by UniProt

Recombinant Human PAI1 (mutated ) protein (ab93232) 使用論文

ab93232 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab93232.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"